Evidence map›Paper›PMID 39253713›Full record

ArticleJACC. Advances2024

Renin-Angiotensin System Inhibition in Patients With Myocardial Injury Complicating Transcatheter Aortic Valve Replacement.

Daijiro Tomii, Dik Heg, Jonas Lanz, Masaaki Nakase, Daryoush Samim, Stefan Stortecky, David Reineke, Stephan Windecker, Thomas Pilgrim

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01368250 (SwissTAVI Registry), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01368250 unknown statusnot on this map

SwissTAVI Registry: Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2011 to 2025Enrolled20,000ConditionsAortic Valve Disease MixedArmsTranscatheter Aortic Valve Implantation
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daijiro TomiiDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Dik HegDepartment of Clinical Research, University of Bern, Switzerland.
Jonas LanzDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Masaaki NakaseDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Daryoush SamimDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Stefan StorteckyDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
David ReinekeDepartment of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Stephan WindeckerDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Thomas PilgrimDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Periprocedural myocardial injury impacts clinical outcome after transcatheter aortic valve replacement (TAVR). The optimal medical management strategy for TAVR-related periprocedural myocardial injury has not been established. Objectives: The authors aimed to investigate the prognostic association of renin-angiotensin system (RAS) inhibitors in patients with periprocedural myocardial injury after TAVR. Methods: In a prospective TAVR registry, patients were retrospectively stratified according to Valve Academic Research Consortium (VARC)-3 periprocedural myocardial injury and RAS inhibitor prescription after TAVR. The main outcomes of interest were prevalence of myocardial injury and cardiovascular death. Logistic and Cox proportional hazards regression were used to analyze outcomes of interest. Results: Among 2,083 eligible patients undergoing TAVR between August 2007 and June 2023, 283 patients (13.8%) developed VARC-3 periprocedural myocardial injury. RAS inhibitors were prescribed in 197 patients (70%) with periprocedural myocardial injury and in 1,251 patients (71.2%) without injury. Compared with patients without periprocedural myocardial injury, patients with myocardial injury had an increased risk of cardiovascular death at 1 year (HR Conclusions: One out of 7 patients undergoing TAVR experienced periprocedural myocardial injury. VARC-3 periprocedural myocardial injury was associated with a 2-fold increased risk of cardiovascular death at 1 year after TAVR. The favorable association of RAS inhibitor prescription was consistent in patients with and without periprocedural myocardial injury. (SwissTAVI Registry; NCT01368250).

Indexed as

aortic stenosisperiprocedural myocardial injuryrenin-angiotensin system inhibitorstranscatheter aortic valve replacementValve Academic Research Consortium

Identifiers

PMID39253713
PMCPMC11381816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.